|Home | About | Journals | Submit | Contact Us | Français|
This reply refers to Weber S, Pongratz G, Schneider M, Brinks R Need for improvements in reported cost-effectiveness of adalimumab in rheumatoid arthritis. doi:10.1007/s00393-016-0255-3
Original version: Gissel, Götz, Repp (2016) Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany. doi:10.1007/s00393-016-0071-9
We thank Sergej Weber, Georg Pongratz, Matthias Schneider and Ralph Brinks for acknowledging the relevance of health economic modeling for biologic treatments for rheumatoid arthritis. We take this opportunity to comment on some health economic concepts that our model is based on:
C. Gissel, G. Götz, and H. Repp declare that they have no competing interests.